Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.

The selective delivery of small interfering RNA (siRNA) to metastatic tumors remains a challenging task. We have developed a nanoparticle (NP) formulation composed of siRNA, a carrier DNA, a polycationic peptide, and cationic liposomes. The NP was obtained by a self-assembling process, followed by surface modification with a polyethylene glycol (PEG)-conjugated ligand, anisamide. The NP was PEGylated and a ligand was presented to target sigma receptor-expressing murine melanoma cells, B16F10. The lung metastasis model was established by intravenous (i.v.) injection of the B16F10 cells into C57BL/6 mice. A mixture of siRNA against MDM2, c-myc, and vascular endothelial growth factor (VEGF) co-formulated in the targeted NP caused simultaneous silencing of each of the oncogenes in the metastatic nodules. Two consecutive i.v. injections of siRNA in the targeted NP significantly reduced the lung metastasis (approximately 70-80%) at a relatively low dose (0.45 mg/kg), whereas free siRNA and the nontargeted NP showed little effect. This targeted NP formulation significantly prolonged the mean survival time of the animals by 30% as compared to the untreated controls. At the therapeutic dose, the targeted NP showed little local and systemic immunotoxicity and did not decrease the body weight or damage the major organs.

[1]  F. Khuri,et al.  Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model , 2005, Clinical Cancer Research.

[2]  I. Greguric,et al.  Preparation and Biologic Evaluation of a Novel Radioiodinated Benzylpiperazine, 123I-MEL037, for Malignant Melanoma , 2007, Journal of Nuclear Medicine.

[3]  Qi Zhou,et al.  Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. , 2007, Cancer research.

[4]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Pradeep Tyagi,et al.  Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells , 2004, International journal of cancer.

[6]  J. Geschwind,et al.  Metastatic Breast Carcinoma Presenting as a Large Pulmonary Embolus: Case Report and Review of the Literature , 2003, American journal of clinical oncology.

[7]  Z. Hua,et al.  Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  D. Schwartz,et al.  CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. , 1997, The Journal of clinical investigation.

[9]  Yun Chen,et al.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Stanley T. Crooke,et al.  Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells , 2007, Nucleic acids research.

[11]  A. Grothey.  Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. , 2006, Seminars in oncology.

[12]  Leaf Huang,et al.  Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[13]  C. Napoli,et al.  Targeting c-Myc, Ras and IGF Cascade to Treat Cancer and Vascular Disorders , 2006, Cell cycle.

[14]  Y. Takakura,et al.  Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[15]  S. Alberts,et al.  Impact of prognostic factors on clinical outcome after resection of colorectal pulmonary metastases. , 2006, Clinical colorectal cancer.

[16]  Anne Gatignol,et al.  Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC , 2007, Nucleic acids research.

[17]  Tyra G. Wolfsberg,et al.  Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[19]  Leaf Huang,et al.  Surface‐Modified LPD Nanoparticles for Tumor Targeting , 2006, Annals of the New York Academy of Sciences.

[20]  T. Murakami,et al.  Chemokine receptors and melanoma metastasis. , 2004, Journal of dermatological science.

[21]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[22]  Da-Qing Yang,et al.  p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. , 2007, Gene.

[23]  S. Jana,et al.  RNA interference: potential therapeutic targets , 2004, Applied Microbiology and Biotechnology.

[24]  P. Picci,et al.  Metastatic Patterns in Osteosarcoma , 1988, Tumori.